Sandoz Group AG Registered Shares SDZXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SDZXF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $33.63
- Day Range
- $31.84–31.84
- 52-Week Range
- $25.75–34.45
- Bid/Ask
- $28.95 / $47.60
- Market Cap
- $13.72 Bil
- Volume/Avg
- 150,294 / 36,577
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- 1.61%
- Total Yield
- —
Company Profile
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz’s total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe’s first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Growth
- Total Number of Employees
- 21,738
- Website
- https://www.sandoz.com
Competitors
Valuation
|
Metric
|
SDZXF
|
TEVA
|
RDY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 5.46 | 19.91 |
Price/Book Value | — | 2.09 | 3.86 |
Price/Sales | — | 0.99 | 3.75 |
Price/Cash Flow | — | 10.86 | 15.29 |
Price/Earnings
SDZXF
TEVA
RDY
Financial Strength
|
Metric
|
SDZXF
|
TEVA
|
RDY
|
|---|---|---|---|
Quick Ratio | 4.37 | 0.54 | 1.80 |
Current Ratio | 4.37 | 1.02 | 2.55 |
Interest Coverage | — | 0.39 | 46.52 |
Quick Ratio
SDZXF
TEVA
RDY
Profitability
|
Metric
|
SDZXF
|
TEVA
|
RDY
|
|---|---|---|---|
Return on Assets (Normalized) | 1,164,892.60% | 6.70% | 15.57% |
Return on Equity (Normalized) | 1,510,121.47% | 39.00% | 21.70% |
Return on Invested Capital (Normalized) | 1,510,121.47% | 13.54% | 20.10% |
Return on Assets
SDZXF
TEVA
RDY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Gygmdyxnj | Ykn | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Lsbrxmvds | Gtdpzv | $69.1 Bil | |
HLN
| Haleon PLC ADR | Wwnhxrt | Xmyb | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Mtrtdzls | Cqy | $15.7 Bil | |
VTRS
| Viatris Inc | Wxrqsxhp | Clmf | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qhxsfcn | Hnlyf | $12.4 Bil | |
CTLT
| Catalent Inc | Qswmrshpd | Bdqllg | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Wdyygjmp | Gptp | $4.5 Bil | |
CURLF
| Curaleaf Holdings Inc | Yqkxcdmhj | Xybm | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Rmjqtmk | Jvltym | $3.5 Bil |